Genentech Inc. (NYSE: DNA) is initially looking like a severe disappointment to those who thought Cramer’s call last week was the right one. The largest biotech in the U.S. posted $0.82 EPS on $3.23 Billion in revenues. The company has also tightened its full-year 2008 non-GAAP earnings forecast to a range of $3.40 to $3.50 per share, revised from $3.35 to $3.45 per share.
First Call had estimates at $0.86 EPS on $3.23 Billion in revenues. For fiscal 2008, estimates are $3.43 EPS on $13.03 Billion in revenues.
The company did have disappointing drug sales as well:
Drug 2008 2007 Change
Rituxan® $651 $582 12%
Avastin®+ $650 $564 15%
Herceptin® $338 $329 3%
Lucentis® $216 $209 3%
Xolair® $129 $120 8%
Tarceva® $119 $102 17%
So far traders do not like this report, but the better news perhaps is that this slightly raised guidance is being treated well. Shares closed down 3% at $75.39. The initial reaction put shares down some 4% but they have recovered back to $75.40.
Jon C. Ogg
July 14, 2008
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
